Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Zhi Ven Fong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6398-413X; OpenAlex author ID A5049233408, A5130250880; NIH RePORTER profile ID 14524039. Sources: OpenAlex.

Their work

Papers
30 (first author 5, last author 9)
Trials
0
Grants
1
Labs led
1
Collaborators
99
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper, 1 grant · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 14 papers

Papers 30

  1. The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. Last author DOI 10.1002/jso.70361↗
  2. Disparities in Pancreatic Cancer Survival: The Overlooked Role of Demographic and Socioeconomic Factors. Co-author DOI 10.1002/jso.70377↗
  3. Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasio… Last author DOI 10.1002/jso.70414↗
  4. Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database. Co-author DOI 10.1007/s12029-026-01545-4↗
  5. Nationwide Trends in Neoadjuvant Chemotherapy Utilization for Pancreatic Adenocarcinoma From 2012 to 2021. Co-author DOI 10.1016/j.jss.2026.09.037↗
  6. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… First author DOI 10.1097/sla.0000000000006432↗
  7. Redefining Resectability in Locally Advanced Pancreatic Cancer: From Anatomy to Judgment. First author DOI 10.1097/xcs.0000000000002030↗
  8. The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. Co-author DOI 10.1177/00031348261495994↗
  9. Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Last author DOI 10.1245/s10434-026-19739-2↗
  10. ASO Author Reflections: It's Not "Just" a Distal Pancreatectomy: The Impact of Postoperative Complications on Adjuvant Therapy Delivery in Left-Side Pancreatic… Last author DOI 10.1245/s10434-026-19786-9↗
  11. ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Last author DOI 10.1245/s10434-026-19795-8↗
  12. Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Last author DOI 10.1245/s10434-026-20347-3↗
  13. Editorial Comment: What's in an Accreditation? Cancer Center Designation and Outcomes in Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20625-0↗
  14. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Last author DOI 10.6004/jnccn.2025.7097↗
  15. Preoperative Biopsy Is Not Associated With Adverse Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Upfront Resection. Co-author DOI 10.1016/j.jss.2025.01.007↗
  16. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  17. Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection. Co-author DOI 10.1016/j.hpb.2023.12.001↗
  18. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.surg.2023.09.041↗
  19. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000006131↗
  20. Pancreatic cancer mortality trends in the United States: how much have we moved the needle? Last author DOI 10.21037/jgo-24-213↗
  21. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. First author DOI 10.1097/sla.0000000000005354↗
  22. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  23. Communicating the Information Needed for Treatment Decision Making Among Patients With Pancreatic Cancer Receiving Preoperative Therapy. Co-author DOI 10.1200/op.21.00388↗
  24. Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management. Co-author DOI 10.6004/jnccn.2021.7009↗
  25. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  26. Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
  27. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Co-author DOI 10.1245/s10434-018-6764-3↗
  28. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24723↗
  29. Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. Co-author DOI 10.1245/s10434-017-5973-5↗
  30. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Co-author DOI 10.1097/ppo.0b013e31827654ea↗

Grants 1

  1. Impact of Volume-Based Regionalization on Access to Care in Patients Undergoing Pancreatectomy F32CA217455↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nabil Wasif · 8 shared papers, 2024–2026 · strength 2.16
  2. Chee‐Chee Stucky · 8 shared papers, 2024–2026 · strength 2.16
  3. Richard J. Bold · 6 shared papers, 2026 · strength 1.83
  4. Motaz Qadan · 8 shared papers, 2020–2026 · strength 1.65
  5. Dillon C. Cheung · 5 shared papers, 2026 · strength 1.59
  6. Keith D. Lillemoe · 10 shared papers, 2017–2026 · strength 1.58
  7. Cristina Rosa Ferrone · 10 shared papers, 2017–2026 · strength 1.58
  8. Stephanie Yu · 4 shared papers, 2026 · strength 1.29
  9. John Andrew Stauffer · 4 shared papers, 2026 · strength 1.17
  10. Cornelius A. Thiels · 4 shared papers, 2026 · strength 1.17
  11. Katherine E. Poruk · 4 shared papers, 2026 · strength 1.17
  12. Maximiliano Servín-Rojas · 4 shared papers, 2024–2026 · strength 0.95
  13. Carlos F. Fernandez-del Castillo · 7 shared papers, 2017–2024 · strength 0.84
  14. Louisa Bolm · 3 shared papers, 2024–2026 · strength 0.74
  15. Carlos Fernández-del Castillo · 3 shared papers, 2019–2026 · strength 0.64
  16. Dillon Cheung · 1 shared paper, 2026 · strength 0.63
  17. Yu-Hui H. Chang · 2 shared papers, 2026 · strength 0.59
  18. Theodore Sunki Hong · 4 shared papers, 2018–2024 · strength 0.57
  19. Jennifer Yon-Li Wo · 4 shared papers, 2018–2024 · strength 0.57
  20. Fidel López‐Verdugo · 3 shared papers, 2023–2024 · strength 0.54
  21. Lawrence Scott Blaszkowsky · 3 shared papers, 2023–2024 · strength 0.50
  22. Aparna R. Parikh · 3 shared papers, 2023–2024 · strength 0.50
  23. Po Hong Tan · 2 shared papers, 2025–2026 · strength 0.41
  24. Guoliang Qiao · 2 shared papers, 2024 · strength 0.38
  25. David P. Ryan · 2 shared papers, 2023–2024 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.